12/14/2023 0 Comments Horizon therapeutics revenue 2020![]() ![]() Third-quarter 20 adjusted EBITDA includes $19.0 million and $4.0 million, respectively, in acquired IPR&D and milestones expenses. These achievements reflect our commitment to bring innovative medicines to more patients in need." "We advanced our pipeline, achieving several important R&D milestones, including completing enrollment in our TEPEZZA trial for chronic/low CAS thyroid eye disease and announcing positive Phase 2 topline results from our dazodalibep trial in Sjögren’s syndrome. "Our third-quarter focus on clinical, commercial and operational execution drove continued progress across our portfolio," said Tim Walbert, chairman, president and chief executive officer, Horizon. First Patient Enrolled in ADX-914 Phase 2 Trial in Collaboration with Q32 Bio -ĭUBLIN, November 02, 2022-( BUSINESS WIRE)-Horizon Therapeutics plc (Nasdaq: HZNP) today announced third-quarter 2022 financial results and increased its full-year 2022 net sales and adjusted EBITDA guidance. Announced Positive Topline Data from Phase 2 Dazodalibep Sjögren’s Syndrome Trial Planning to Initiate a Phase 3 Clinical Program in 2023. Completed Enrollment in TEPEZZA Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) Trial Topline Results Expected in the Second Quarter of 2023. Peak Annual Net Sales Expectations to Greater than $1.5 Billion. Peak Annual Net Sales Expectations to Greater than $1 Billion, Bringing Global Peak Annual Net Sales Expectations to Greater than $4 Billion. Increasing Full-Year 2022 KRYSTEXXA Net Sales Growth Expectations to Approximately 25%. Continue to Expect Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High Teens. Increasing Full-Year 2022 Adjusted EBITDA Guidance to $1.32 Billion to $1.34 Billion, Which Includes $52.5 Million of Acquired IPR&D and Milestones Expenses. Increasing Full-Year 2022 Net Sales Guidance to $3.59 Billion to $3.61 Billion. 30, 2022 -įull-Year 2022 Guidance and Peak Annual Net Sales Expectations: Cash Position of $2.13 Billion as of Sept. KRYSTEXXA ® (pegloticase injection) Net Sales of $191.6 Million. TEPEZZA ® (teprotumumab-trbw) Net Sales of $490.9 Million. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.- GAAP Net Income of $135.8 Million Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones Expenses. BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. ![]() ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). ![]() The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. Horizon Therapeutics plc is an Ireland-based global biotechnology company. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |